Skip to main content
Equibles
AVBP logo

AVBP · ArriVent BioPharma, Inc.

Track AVBP — free

Use AVBP with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$30.95 -0.08 (-0.26%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$1.53B
Shares
49.31M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Net Income
-$166.31M -106.6%
FY2025 Net Income FY2023–FY2025
Diluted EPS
-$4.32 -68.8%
FY2025 Diluted EPS FY2023–FY2025
Operating Cash Flow
-$160.59M -128.7%
FY2025 Operating Cash Flow FY2023–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2025 FY2024 FY2023
$144.3M $153.35M $79M $64.88M
$31.64M $24.18M $15.3M $9.71M
— -$3.03M — —
$175.94M $177.53M $94.31M $74.59M
-$175.94M -$177.53M -$94.31M -$74.59M
-$163.74M -$166.31M -$80.49M -$69.33M
-$163.98M -$166.08M -$80.7M -$69.33M
USD/shares -$3.53 -$4.32 -$2.56 -$32.38
USD/shares -$3.53 -$4.32 -$2.56 -$32.38
shares — 38.46M 31.47M 2.14M
shares — 38.46M 31.47M 2.14M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.

Debt Profile

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Coverage backlog: 22 eligible filings and 0 covenant artifacts have no current-version terminal extraction result. This includes untouched sources and sources on the retry ladder.
No terminal debt extraction result is available yet; this is not evidence that the company has no debt.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 6.50×
EV/EBIT
—
Peer median 13.00×
P/E (TTM)
—
Peer median 18.22×

Peer medians compare against the 272 similar-size Biotechnology companies (of 515 listed).

Key facts CIK 1868279 CUSIP 04272N102 13F (30d) 133 filings 133 filers Visit website Investor relations